SurvivorNet on MSN

Enabling hope: Lilly’s head of oncology has a hugely ambitious plan to create the next wave of cancer drugs & incredible resources to make it happen

For Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, the mission is clear: bring better cancer ...
Fierce Pharma

ASH: Lilly oncology chief sees sweet spot for Jaypirca in 2nd-line CLL despite 1st-line trial wins

In the world of oncology drug development, the standard playbook is simple: race to earlier lines of treatment, where patient ...
Fierce Biotech

With weight loss windfall, Lilly looks to become ‘backbone’ of global innovation: exec

With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli ...
Fierce Pharma

Lilly shifts ambition for broader oral SERD label to largest oncology trial in company history

Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...

Is Eli Lilly a buy before 2026?

Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...
Nasdaq

Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting

Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to be presented as a late-breaking oral ...
Becker's Hospital Review

Eli Lilly buys Loxo Oncology for $8B

Eli Lilly plans to acquire Loxo Oncology for $8 billion in cash to expand its portfolio of cancer medications, according to CNBC. Loxo Oncology is developing a pipeline of targeted oncology treatments ...